Molecular networks for the study of TCM Pharmacology

To target complex, multi-factorial diseases more effectively, there has been an emerging trend of multi-target drug development based on network biology, as well as an increasing interest in traditional Chinese medicine (TCM) that applies a more holistic treatment to diseases. Thousands of years' clinic practices in TCM have accumulated a considerable number of formulae that exhibit reliable in vivo efficacy and safety. However, the molecular mechanisms responsible for their therapeutic effectiveness are still unclear. The development of network-based systems biology has provided considerable support for the understanding of the holistic, complementary and synergic essence of TCM in the context of molecular networks. This review introduces available sources and methods that could be utilized for the network-based study of TCM pharmacology, proposes a workflow for network-based TCM pharmacology study, and presents two case studies on applying these sources and methods to understand the mode of action of TCM recipes.

[1]  Adam J. Smith,et al.  The Database of Interacting Proteins: 2004 update , 2004, Nucleic Acids Res..

[2]  Doris Marko,et al.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases , 1999, Nature Cell Biology.

[3]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[4]  Ian M. Donaldson,et al.  The Biomolecular Interaction Network Database and related tools 2005 update , 2004, Nucleic Acids Res..

[5]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[6]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[7]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[8]  J. Jenkins,et al.  Prediction of Biological Targets for Compounds Using Multiple‐Category Bayesian Models Trained on Chemogenomics Databases. , 2006 .

[9]  J. Rich,et al.  Malignant glioma drug discovery – targeting protein kinases , 2007, Expert opinion on drug discovery.

[10]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[11]  De-Xin Kong,et al.  Where is the hope for drug discovery? Let history tell the future. , 2009, Drug discovery today.

[12]  M. Gerstein,et al.  Comparing protein abundance and mRNA expression levels on a genomic scale , 2003, Genome Biology.

[13]  Gabriele Ausiello,et al.  MINT: the Molecular INTeraction database , 2006, Nucleic Acids Res..

[14]  Hai-long Yang.  Ganoderic acid produced from submerged culture of Ganoderma lucidum induces cell cycle arrest and cytotoxicity in human hepatoma cell line BEL7402 , 2005, Biotechnology Letters.

[15]  M. Danhof,et al.  Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?". , 2009, Journal of ethnopharmacology.

[16]  F. Azuaje,et al.  Linking Gene Expression and Functional Network Data in Human Heart Failure , 2007, PloS one.

[17]  D. Sliva,et al.  Ganoderma lucidum in cancer research. , 2006, Leukemia research.

[18]  Pankaj Agarwal,et al.  A Pathway-Based View of Human Diseases and Disease Relationships , 2009, PloS one.

[19]  B Xie,et al.  Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. , 2009, Drug discovery today.

[20]  A. Nahrstedt,et al.  Phenolic compounds from Hypericum perforatum. , 2002, Planta medica.

[21]  S. Lipton.  Turning down, but not off , 2004, Nature.

[22]  Jing Zhao,et al.  Complex networks theory for analyzing metabolic networks , 2006, q-bio/0603015.

[23]  Ryan P. Million,et al.  Tapping the potential of fixed-dose combinations , 2007, Nature Reviews Drug Discovery.

[24]  J. Yuen,et al.  Anticancer Effects of Ganoderma lucidum: A Review of Scientific Evidence , 2005, Nutrition and cancer.

[25]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[26]  Nan-nan Chen,et al.  [Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases]. , 2008, Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine.

[27]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[28]  Xueguo Chen,et al.  Strategy for analysis and screening of bioactive compounds in traditional Chinese medicines. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[29]  J. Burbaum,et al.  Proteomics in drug discovery. , 2002, Current opinion in chemical biology.

[30]  T. Pawson,et al.  Network medicine , 2008, FEBS letters.

[31]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[32]  Yu Zong Chen,et al.  TRMP: a database of therapeutically relevant multiple pathways , 2004, Bioinform..

[33]  Martin Vingron,et al.  IntAct: an open source molecular interaction database , 2004, Nucleic Acids Res..

[34]  H. Woelk.  Comparison of St John's wort and imipramine for treating depression: randomised controlled trial , 2000, BMJ : British Medical Journal.

[35]  R. Verpoorte,et al.  Ethnopharmacology and systems biology: a perfect holistic match. , 2005, Journal of ethnopharmacology.

[36]  H. Wagner,et al.  Inhibition of MAO by Fractions and Constituents of Hypericum Extract , 1994 .

[37]  C. Ung,et al.  Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? , 2003, Natural product reports.

[38]  L. Lai,et al.  Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.

[39]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[40]  Hui Li,et al.  The use of logic relationships to model colon cancer gene expression networks with mRNA microarray data , 2008, J. Biomed. Informatics.

[41]  Changyu Shen,et al.  Mining Alzheimer Disease Relevant Proteins from Integrated Protein Interactome Data , 2005, Pacific Symposium on Biocomputing.

[42]  G. Harrer,et al.  Bicaudate index on magnetic resonance imaging: effects of normal aging. , 1994 .

[43]  U. Simmen,et al.  Antagonist effect of pseudohypericin at CRF1 receptors. , 2003, European journal of pharmacology.

[44]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[45]  Ioannis Xenarios,et al.  DIP: The Database of Interacting Proteins: 2001 update , 2001, Nucleic Acids Res..

[46]  Daniel Jones,et al.  Pathways to cancer therapy , 2008, Nature Reviews Drug Discovery.

[47]  C. J. Van der Schyf,et al.  NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort. , 2006, Journal of pharmacological sciences.

[48]  J. Doyle,et al.  Metabolic syndrome and robustness tradeoffs. , 2004, Diabetes.

[49]  Weidong Zhang,et al.  Analysis of the constituents in rat plasma after oral administration of Shexiang Baoxin pill by HPLC-ESI-MS/MS. , 2009, Biomedical chromatography : BMC.

[50]  Madhukar S. Dasika,et al.  A computational framework for the topological analysis and targeted disruption of signal transduction networks. , 2006, Biophysical journal.

[51]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[52]  Pall I. Olason,et al.  Integrative analysis for finding genes and networks involved in diabetes and other complex diseases , 2007, Genome Biology.

[53]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[54]  Min He,et al.  Traditional Chinese Medicine Database and Application on the Web , 2001, J. Chem. Inf. Comput. Sci..

[55]  V. Lallemand-Breitenbach,et al.  How acute promyelocytic leukaemia revived arsenic , 2002, Nature Reviews Cancer.

[56]  T. Niwa.  Prediction of biological targets using probabilistic neural networks and atom-type descriptors. , 2004, Journal of medicinal chemistry.

[57]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[58]  Y. Z. Chen,et al.  Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation , 2006, British journal of pharmacology.

[59]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[60]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[61]  P. Rothman,et al.  IL-4/IL-13 signaling beyond JAK/STAT. , 2000, The Journal of allergy and clinical immunology.

[62]  H. Volz.  Controlled Clinical Trials of Hypericum Extracts in Depressed Patients - an Overview , 1997, Pharmacopsychiatry.

[63]  J. Scott Dixon,et al.  Flexible ligand docking using a genetic algorithm , 1995, J. Comput. Aided Mol. Des..

[64]  Stefan Günther,et al.  SuperPred: drug classification and target prediction , 2008, Nucleic Acids Res..

[65]  A. Harder,et al.  Identification of coexpressed gene clusters in a comparative analysis of transcriptome and proteome in mouse tissues. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[67]  P. Barnes,et al.  New drugs for asthma , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[68]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[69]  P. Bork,et al.  Large‐scale prediction of drug–target relationships , 2008, FEBS letters.

[70]  Nir Friedman,et al.  A functional and regulatory map of asthma. , 2008, American journal of respiratory cell and molecular biology.

[71]  Hawoong Jeong,et al.  A protein interaction network associated with asthma. , 2008, Journal of theoretical biology.

[72]  Haiyan Hu,et al.  Networking Pathways Unveils Association Between Obesity and Non-Insulin Dependent Diabetes Mellitus , 2007, Pacific Symposium on Biocomputing.

[73]  F. Bruggeman,et al.  Cancer: a Systems Biology disease. , 2006, Bio Systems.

[74]  M. Millan.  Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, Pharmacology & therapeutics.

[75]  Jing Zhao,et al.  Hierarchical modularity of nested bow-ties in metabolic networks , 2006, BMC Bioinformatics.

[76]  Chuan Zhang,et al.  Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. , 2006, Planta medica.

[77]  B. Leonard.  Inflammation, Depression and Dementia: Are they Connected? , 2007, Neurochemical Research.

[78]  Zhi-xiang Shen,et al.  Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia , 2008, Proceedings of the National Academy of Sciences.

[79]  L. Kong,et al.  Fractionation and analysis of Artemisia capillaris Thunb. by affinity chromatography with human serum albumin as stationary phase. , 2000, Journal of chromatography. A.

[80]  K. Gunsalus,et al.  Network modeling links breast cancer susceptibility and centrosome dysfunction. , 2007, Nature genetics.

[81]  Luay Nakhleh,et al.  Hypothesis Generation in Signaling Networks , 2006, J. Comput. Biol..

[82]  Bin Song,et al.  Mining Metabolic Networks for Optimal Drug Targets , 2007, Pacific Symposium on Biocomputing.

[83]  S. Kasif,et al.  Network-Based Analysis of Affected Biological Processes in Type 2 Diabetes Models , 2007, PLoS genetics.

[84]  Edda Klipp,et al.  TIde: a software for the systematic scanning of drug targets in kinetic network models , 2009, BMC Bioinformatics.

[85]  P. Rothman,et al.  JAK-STAT signaling in asthma. , 2002, The Journal of clinical investigation.

[86]  Y. Kimura,et al.  Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. , 2002, Anticancer research.

[87]  Krin A. Kay,et al.  The implications of human metabolic network topology for disease comorbidity , 2008, Proceedings of the National Academy of Sciences.

[88]  Jordi Mestres,et al.  A chemogenomic approach to drug discovery: focus on cardiovascular diseases. , 2009, Drug discovery today.

[89]  Yadong Wang,et al.  Constructing disease-specific gene networks using pair-wise relevance metric: Application to colon cancer identifies interleukin 8, desmin and enolase 1 as the central elements , 2008, BMC Systems Biology.

[90]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[91]  István A. Kovács,et al.  Drug-therapy networks and the prediction of novel drug targets , 2008, Journal of biology.

[92]  J. Drewe,et al.  Transport of amentoflavone across the blood-brain barrier in vitro. , 2002, Planta medica.

[93]  M. Oti,et al.  The modular nature of genetic diseases , 2006, Clinical genetics.

[94]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[95]  R. Kohnen,et al.  Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. , 1999, BMJ.

[96]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[97]  Dietmar Schomburg,et al.  Observing local and global properties of metabolic pathways: "load points" and "choke points" in the metabolic networks , 2006, Bioinform..

[98]  G. Harrer,et al.  Clinical investigation of the antidepressant effectiveness of hypericum. , 1994, Journal of geriatric psychiatry and neurology.

[99]  Maricel G. Kann,et al.  Protein interactions and disease: computational approaches to uncover the etiology of diseases , 2007, Briefings Bioinform..

[100]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[101]  David B. Searls,et al.  Literature mining in support of drug discovery , 2008, Briefings Bioinform..

[102]  J. Hölzl,et al.  Pharmacokinetic Test of [14 C]-Labelled Hypericin and Pseudohypericin from Hypericum perforatum and Serum Kinetics of Hypericin in Man , 1991 .

[103]  De-An Guo,et al.  Proteomics Characterization of the Cytotoxicity Mechanism of Ganoderic Acid D and Computer-automated Estimation of the Possible Drug Target Network*S , 2008, Molecular & Cellular Proteomics.

[104]  A. Bender,et al.  In silico target fishing: Predicting biological targets from chemical structure , 2006 .

[105]  R. Ravi,et al.  A nearly best-possible approximation algorithm for node-weighted Steiner trees , 1993, IPCO.

[106]  P. Gao,et al.  Astragaloside IV dilates aortic vessels from normal and spontaneously hypertensive rats through endothelium-dependent and endothelium-independent ways. , 2006, Planta medica.

[107]  Tingjun Hou,et al.  A 3D Structure Database of Components from Chinese Traditional Medicinal Herbs , 2002, J. Chem. Inf. Comput. Sci..

[108]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[109]  B. Roth,et al.  In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs , 2002, Psychopharmacology.

[110]  S. Choi,et al.  Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3 , 1999, Experimental & Molecular Medicine.

[111]  Feng Chen,et al.  Unraveling the molecular targets of natural products: Insights from genomic and proteomic analyses , 2008, Proteomics. Clinical applications.

[112]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[113]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[114]  A. Singer,et al.  Hyperforin activates nonselective cation channels (NSCCs) , 2005, British journal of pharmacology.

[115]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[116]  Mate S. Szalay,et al.  How to design multi-target drugs , 2007, Expert opinion on drug discovery.

[117]  H M Thiede,et al.  Inhibition of MAO and COMT by hypericum extracts and hypericin. , 1994, Journal of geriatric psychiatry and neurology.

[118]  A. Barabasi,et al.  A Protein–Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration , 2006, Cell.

[119]  Hong-yu Zhang,et al.  How Many Traditional Chinese Medicine Components Have Been Recognized by Modern Western Medicine? A Chemoinformatic Analysis and Implications for Finding Multicomponent Drugs , 2008, ChemMedChem.

[120]  Jing Zhao,et al.  Bow-tie topological features of metabolic networks and the functional significance , 2006 .

[121]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[122]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[123]  Lunzhao Yi,et al.  Traditional Chinese medicine and separation science. , 2008, Journal of separation science.

[124]  W-C Hwang,et al.  Identification of Information Flow‐Modulating Drug Targets: A Novel Bridging Paradigm for Drug Discovery , 2008, Clinical pharmacology and therapeutics.

[125]  A. Barabasi,et al.  Lethality and centrality in protein networks , 2001, Nature.

[126]  Ralf Herwig,et al.  Meta-Analysis Approach identifies Candidate Genes and associated Molecular Networks for Type-2 Diabetes Mellitus , 2008, BMC Genomics.

[127]  István A. Kovács,et al.  How to design multi-target drugs , 2007, Expert opinion on drug discovery.

[128]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[129]  Vladimir Poroikov,et al.  PASS: prediction of activity spectra for biologically active substances , 2000, Bioinform..

[130]  K. Oka,et al.  A strategy for discovering biologically active compounds with high probability in traditional Chinese herb remedies: an application of saiboku-to in bronchial asthma. , 1992, Analytical biochemistry.

[131]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.